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Introduction
Allogeneic hematopoietic stem cell transplantation is current-
ly the most effective treatment in eligible patients with acute
myeloid leukemia (AML) or high-risk myelodysplastic syn-
dromes (MDS).1 This approach was initially reserved for young,
fit patients, given the high toxicity related to myeloablative con-
ditioning regimens.2 Older patients were usually not considered
for standard myeloablative allogeneic hematopoietic stem cell
transplantation because of additional toxicities due to age and
associated comorbidities. However, the incidence of AML and
MDS tends to increase with age.3 Moreover, even in younger
patients, standard myeloablative conditioning regimens cannot
be performed safely in cases of comorbidities that would lead to
a higher risk of non-relapse mortality. Therefore, most AML or
MDS patients with potential indications could not benefit from
allogeneic hematopoietic stem cell transplantation. So-called
non-myeloablative or reduced-intensity conditioning regimens
have been developed in order to reduce the non-relapse mortal-
ity.4-7 This approach focuses on the allogeneic graft-versus-
leukemia effect8 and was thought to allow disease control,
despite the reduction of the cytotoxicity of the antileukemic
conditioning, while decreasing transplant-related morbidity and
mortality. Early reports were encouraging and non-myeloabla-
tive and reduced-intensity conditioning regimens are now
widely used. However, several retrospective studies have raised
concerns about disease control when reducing the conditioning
intensity.9-14 Indeed, it is probable that the choice of a condition-
ing regimen should be based not only on the patients’ character-
istics (age and comorbidities) but also on disease type and
stage6,15-17 and prognostic factors (mainly cytogenetic and molec-
ular markers in myeloid malignancies15,18). Myeloablative
reduced-toxicity regimens that combine truly myeloablative
doses of alkylating agents or intermediate doses of total body
irradiation and highly immunosuppressive agents have been
developed to achieve better disease control with an acceptable
non-relapse mortality.19-21 However, the ideal conditioning regi-
men has not yet been found. The association of busulfan and
fludarabine has been widely used.19,22 We initially reported that
this association, together with a low dose of rabbit anti-thy-
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The introduction of reduced intensity/toxicity conditioning regimens has allowed allogeneic hematopoietic cell
transplantation to be performed in patients who were previously considered too old or otherwise unfit. Although
it led to a reduction in non-relapse mortality, disease control remains a major challenge. We studied the outcome
of 165 patients with acute myeloid leukemia (n=124) or myelodysplastic syndrome (n=41) transplanted after con-
ditioning with fludarabine (30 mg/m2/day for 5 days), intravenous busulfan (either 260 mg/m2: reduced intensity
conditioning, or 390–520 mg/m2: reduced toxicity conditioning), and rabbit anti-thymoglobulin (2.5 mg/kg/day for
2 days). The median age of the patients at transplantation was 56.8 years. The 2-year relapse incidence was 29%
(23% versus 39% for patients transplanted in first complete remission and those transplanted beyond first complete
remission, respectively; P=0.008). The 2-year progression-free survival rate was 57% (95% CI: 49.9–65). It was
higher in the groups with favorable or intermediate cytogenetics than in the group with unfavorable cytogenetics
(72.7%, 60.5%, and 45.7%, respectively; P=0.03). The cumulative incidence of grades 2–4 and 3–4 acute graft-ver-
sus-host disease at day 100 was 19.3% and 7.9%, respectively. The cumulative incidence of chronic graft-versus-
host disease at 1 year was 21.6% (severe forms: 7.8%). Non-relapse mortality at 1 year reached 11%. The 2-year
overall survival rate was 61.8% (95% CI: 54.8–69.7). Unfavorable karyotype and disease status beyond first com-
plete remission were associated with a poorer survival. This well-tolerated conditioning platform can lead to long-
term disease control and offers possibilities of modulation according to disease stage or further development.
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ABSTRACT
Reduced-toxicity/intensity conditioning in AML/MDS
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moglobulin, held some promise.22 However, the low dose of
rabbit anti-thymoglobulin was associated with relatively
high incidences of acute and chronic graft-versus-host disease
(GVHD), which affected survival. We therefore increased
the dose of rabbit anti-thymoglobulin to reduce the inci-
dence of GVHD without increasing the relapse rate.23 The
refinement of rabbit anti-thymoglobulin and intravenous
(i.v.) busulfan doses in combination with fludarabine
allowed us to develop a safe and flexible reduced-
intensity/toxicity conditioning platform. In this paper, we
describe the outcome of 165 high-risk AML and MDS
patients treated with this conditioning.
Methods
Patients’ and disease characteristics
Patients from two associated French transplantation centers
transplanted between January 2005 and December 2011 were eligi-
ble if they: (i) were adult patients (≥18 years); (ii) had de novo or sec-
ondary AML or MDS; (iii) received a reduced-intensity or reduced-
toxicity conditioning regimen including fludarabine, i.v. busulfan
and rabbit anti-thymoglobulin 5 mg/kg; (iv) had an HLA-identical
matched related, or matched or mismatched unrelated donor; and
(v) received peripheral blood or bone marrow stem cells as the graft. 
Clinical and biological data were prospectively collected from a
shared patients’ database and were crosschecked with information
from individual institutional clinical files. Morbidity and mortality
risks related to transplantation were assessed by the comorbidity
index described by Sorror et al.24 Patients were considered to be at
high risk when their score was ≥3.25
Disease status at transplantation was defined according to previ-
ously described international criteria.26,27 Karyotype was defined as
favorable, intermediate, and unfavorable as described by Döhner et
al.27
FMS-like tyrosine kinase 3/internal tandem duplication (FLT3-
ITD), nucleophosmin 1 (NPM1) and CCAAT/enhancer binding
protein alpha (CEBPα) mutation status was available for 47 cases
among 81 AML patients with an intermediate karyotype.
Ethical committee approval
All patients gave informed consent to clinical investigations;
according to standard practice in France both institutional review
boards approved the retrospective design of the study.
Transplant characteristics
All patients received a conditioning regimen including fludara-
bine, i.v. busulfan and rabbit anti-thymoglobulin 5 mg/kg. A condi-
tioning regimen using 2 days of busulfan (total dose 260 mg/m2)
was defined as reduced-intensity conditioning, whereas regimens
involving 3 or 4 days of busulfan (390 mg/m2 and 520 mg/m2,
respectively) were defined as reduced-toxicity conditioning.28 The
total dose of busulfan was determined by the attending physician
who took into consideration the patient’s age and comorbidities.
Supportive care was performed as previously described.22 Acute and
chronic GVHD were graded according to the National Institutes of
Health classification.29,30
For details, see the Online Supplementary Methods.
Statistical analyses
The outcomes of interest were cumulative incidence of relapse,
non-relapse mortality, overall survival, and progression-free sur-
vival, and were determined from the date of transplantation. When
AML relapsed or progressed, relapse/progression was considered as
a cause of death regardless of other events. All deaths without
relapse/progression were considered non-relapse mortality. Death
from any cause was a relevant event for overall survival. Events for
progression-free survival were relapse or death from any cause.
Overall survival and progression-free survival rates were estimated
using the Kaplan–Meier method,31 and the log-rank test was applied
to compare survival probabilities between subgroups of patients.
Death without evidence of progression was treated as a competing
risk in the analyses of cumulative incidence of relapse, whereas
death following relapse or progression was treated as a competing
risk when analyzing non-relapse mortality.32 The Prentice estima-
tion and Gray test were used to analyze cumulative incidence of
relapse and non-relapse mortality. Hazard ratios (HR) and their
95% confidence intervals (95% CI) were estimated with Cox pro-
portional hazard (overall survival, progression-free survival) and
Fine and Gray (cumulative incidence of relapse and non-relapse
mortality) models. All statistical analyses were performed using
R.2.14.1 statistical software and SPSS (SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics
The study population comprised 165 patients with AML
(n=124) or MDS (n=41) who met the inclusion criteria. The
median age of the patients at transplantation was 56.8 years
(range, 18–71). Disease type, disease status at time of trans-
plantation, karyotype, donor type, stem cell source and con-
ditioning intensity (i.e., total dose of busulfan) are presented
in Table 1.
Comorbid conditions assessed by the comorbidity index
score described by Sorror et al. were determined in 58% of
the patients: 71% of patients had a score ≥2, and 47.1% had
a score ≥3. There was no significant difference in scores
between patients under or over 55 years of age.
Additionally, we did not observe a significant difference in
the comorbidity score between the two conditioning groups
(score ≥2 in 72% of cases in the busulfan 260 mg/m2 group
versus 68% in the 390 mg/m2 or 520 mg/m2 group). Patients
over 55 years old at the time of transplantation (n=89;
53.9%) received reduced-intensity conditioning (busulfan =
260 mg/m2) in most cases (75/89; 84.3%), although 14
received reduced-toxicity conditioning [busulfan 390 mg/m2
in 11 (12.4%), and bulsulfan 520 mg/m2 in 3 (3.4%) cases].
Patients under 55 years of age (n=76) received 260 mg/m2,
390 mg/m2, and 520 mg/m2 of busulfan intravenously in 31
(40.8%), 24 (31.6%), and 21 (27.6%) cases, respectively.
Post-transplant outcomes
Engraftment
Full engraftment occurred in all patients except for one.
This patient with MDS had progressive secondary graft fail-
ure. He is still alive 25 months after transplantation and is
receiving adapted supportive care.
Relapse and progression-free survival
Overall, 56 patients relapsed, within a median time after
transplantation of 164.5 days (range, 17-1520). The 1- and 2-
year cumulative incidences of relapse were 24% and 29%,
respectively. Three patients received a second allogeneic
hematopoietic stem cell transplant after the relapse. Patients
beyond first complete remission had a higher 2-year cumu-
lative incidence of relapse (23% versus 39% for first com-
plete remission and non-first complete remission patients,
respectively; P=0.008). There was no difference in relapse
rates considering the total dose of busulfan, the donor type,
the cytogenetic status or age under or over 55 years (Table
2). After adjusrment for other variables, the prognostic value
of disease status remained the only significant value (HR
2.32, 95% CI: 1.23-4.39 for patients not in first complete
remission; P=0.009)
The 2-year progression-free survival rate was 57% (95%
CI: 49.9–65) (Figure 1A). The rate was higher in the groups
with favorable or intermediate cytogenetics than in the
group with unfavorable cytogenetics (72.7%, 60.5%, and
45.7%, respectively; P=0.03) (Table 2). Patients beyond first
complete remission had a lower progression-free survival
rate (48.3% versus 62.1%; P=0.04). Age at transplantation,
disease type, and conditioning had no impact on progres-
sion-free survival. Disease status beyond first complete
remission and adverse karyotype remained significantly
associated with lower progression-free survival rates after
adjustment for other variables (Table 3).
Non-relapse mortality
The non-relapse mortality rates at 3, 12, and 24 months
after transplantation were 2%, 11%, and 14%, respectively.
The patients who received reduced-toxicity conditioning
(i.v. busulfan 390 mg/m2 or 520 mg/m2) had a lower non-
relapse mortality (3.4% at 24 months versus 19.9% for the
remaining patients; P=0.003). However, these patients were
younger (median age: 46.5 versus 57.6 years; P=0.001).
The main cause of non-relapse mortality was acute or
chronic GVHD (15 cases). Fatal infection without GVHD
occurred in four cases. One patient died from secondary
neoplasm, one from relapse of primary breast cancer, two
from heart failure, one from an accidental fall, and one from
sinusoid obstruction syndrome.
We found no impact of donor type, disease status, age
under or over 55 years or comorbidity index score on non-
relapse mortality (Table 2).
Acute graft-versus-host disease
Patients developed acute GVHD at a median time of 35
days after hematopoietic stem cell transplantation (range, 8–
153 days). The cumulative incidence of grades 2–4 acute
GVHD was 19.3% at day 100. There was no significant dif-
ference between patients younger and older than 55 years
(13.1% versus 24.7% at day 100, respectively; P=0.1). The
cumulative incidence of grades 3–4 acute GVHD was 7.9%
at day 100. Patients over 55 years had a higher cumulative
incidence of grades 3–4 acute GVHD than the younger
patients (12.4 versus 2.6% at day 100, respectively; P=0.05).
Neither donor type nor total dose of busulfan had any sig-
nificant impact on acute GVHD.
Chronic graft-versus-host disease
The cumulative incidences of chronic GVHD (all grades)
were 15.1% and 21.8% at 6 and 12 months, respectively.
The cumulative incidences of severe chronic GVHD
C. Oudin et al.
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Table 1. Patients’ and transplant characteristics.
Patients’ characteristics All patients Reduced-intensity Reduced-toxicity conditioning P-value
(n=165) conditioning group group (busulfan 390 or
(busulfan 260 mg/m2) 520 mg/m2) (n=59)
(n=106)
Age at transplantation (years), mean 56.8 (18-71) 60.4 (23.5-70) 47.6 (18-67.4) < 0.01
Gender n. (%)
Male 83 (50.3) 55 (51.9) 28 (47.5) 0.58
Female 82 (49.7) 51 (48.1) 31 (52.5)
Diagnosis n. (%)
AML 124 (75.2) 77 (72.6) 47 (79.7) 0.3
MDS 41 (24.8) 29 (27.4) 12 (20.3)
Karyotype n. (%)
Favorable 11 (6.7) 7 (6.8) 4 (6.9)
Intermediate 104 (63) 69 (67) 35 (60.3)
Unfavorable 46 (27.9) 27 (26.2) 19 (32.8) 0.6
Unknown 4 (2.4%) 3 1
Disease status n. (%)
AML CR1 93 (56.4) 58 (54.7) 35 (59.3)
AML ≥CR2 23 (13.9) 15 (14.2) 8 (13.6)
AML refractory 8 (4.8) 4 (3.8) 4 (6.8) 0.4
MDS CR 10 (6.1) 9 (8.5) 1 (1.7)
MDS SD/PR 31 (18.8) 20 (19.8) 11 (18.6)
Transplant characteristics
Donor type n. (%)
Matched related donor 92 (55.8) 61 (57.5) 31 (52.5)
Matched unrelated donor 55 (33.3) 37 (34.9) 18 (30.5)
Mismatched unrelated donor 18 (10.9) 8 (7.5) 10 (16.9) 0.17
Cell source n. (%)
Peripheral blood stem cells 157 (95.2) 99 (93.4) 58 (98.3)
Bone marrow 8 (4.8) 7 (6.6) 1 (1.7) 0.26
AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, CR1: first completed remission, CR2: second complete remission. SD/PR: stable disease/progressive disease. 
(National Institutes of Health classification) were 5.4% and
7.8% at 6 and 12 months, respectively. There was no differ-
ence in GVHD incidences between patients divided accord-
ing to age at transplantation (under or over 55 years), donor
type, comorbidity index or busulfan dose.
Among patients suffering from chronic GVHD who sur-
vived more than 1 year after transplantation (n=35), 19 were
able to discontinue steroid therapy for chronic GVHD
before 1 year after the transplant (54.3%).
Overall survival
At the time of the last follow-up, 93 (56.4%) patients were
alive. The median follow-up duration for living patients was
38.9 months (range, 19.8–75.7 months). The main cause of
death was disease relapse/progression (n=47; 65.3%).
The 2- and 5-year overall survival estimates were 61.8%
(95% CI: 54.8–69.7) and 53.8% (95% CI: 45.5–63.6), respec-
tively (Figure 1B). Age beyond 55 years was not statistically
associated with a poorer overall survival.
Unfavorable karyotype and disease status beyond first
complete remission were significantly associated with a
poorer overall survival (Table 2). In multivariate analysis, the
cytogenetic status was the only factor that remained statis-
tically significant (HR 2.2; 95% CI: 1.33–3.65 for unfavorable
karyotype; P=0.002).
Discussion
The association of fludarabine, busulfan, and rabbit anti-
thymoglobulin as a platform for a conditioning regimen has
been used for more than a decade in our institutions, with
Table 2. Univariate analysis. 
2- year OS 2-year PFS 2-year relapse incidence 1-year NRM
%OS P value HR 95% CI % PFS P value HR 95%CI % P value HR 95% CI % P value HR 95% CI
Disease status
CR1 (n=103) 64.1 ref 62.1 ref 23.3 ref 11 ref
>CR1 (n=62) 58 0.3 1.25 0.78-2 48.3 0.046 1.56 1.01-2.43 38.8 0.008 2.02 1.2-3.41 11 0.7 0.89 0.37-2.1
Karyotype
Favorable (n=11) 90.9 ref 72.7 ref 27.3 0
Intermediate (n=104) 65.4 0.09 5.7 0.76-40 60.5 0.2 2.4 0.63-6.5 26 ref 9.6 ref
Unfavorable (n=46) 45.7 0.018 11.05 1.49-81 45.7 0.03 3.6 1.08-11.9 34.8 0.12 1.49 0.9-2.44 17 0.3 1.55 0.68-3.49
Age
≤ 55 years (n=76) 67.1 ref 61.8 ref 28.9 ref 6.6 ref
> 55 years (n=89) 57.3 0.09 1.5 0.92-2.42 52.8 0.16 1.36 0.8-2.13 29.2 0.69 1.12 0.66-1.89 15 0.11 2.04 0.84-4.9
Total dose of busulfan
260 mg/m2 (n=106) 57.5 ref 52.8 ref 27.4 ref 15 ref
390 or 520 mg/m2 (n=59) 69.5 0.15 0.68 0.4-1.14 64.4 0.24 0.75 0.46-1.21 32.2 0.36 1.28 0.75-2.19 3.4 0.014 0.15 0.03-0.68
Disease type
AML (n=124) 65,3 ref 61.3 ref 25 ref 11 ref
MDS (n=41) 51.2 0.047 1.65 1.07-2.73 43.6 0,024 1.73 1.007-2.72 41.7 0.015 1.97 1.15-3.39 12 0.88 1.07 0.42-2.71
CR1: first complete remission; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; OS: overall survival; PFS: progression-free survival; NRM: non-relapse mortality; Ref: reference.
Statistically significant differences are shown in bold.
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encouraging results after continuous optimization.7,22,33 We
recently showed that within this association, increasing the
dose of rabbit anti-thymoglobulin from 2.5 mg/kg to 5
mg/kg reduced the incidence of acute and chronic GVHD
without increasing the relapse rate.23 Here, we aimed to eval-
uate the results of this combination in terms of disease con-
trol in a larger group of patients with myeloid malignancies.
Our patients were characterized by a relatively high risk
of relapse: 37.6% were beyond first complete remission and
27.9% had an unfavorable karyotype. However, the cumu-
lative incidences of relapse and progression-free survival
were promising, 29.1% and 57%, respectively, at 2 years.
These results compare favorably with those of previous
studies based on reduced toxicity conditioning (2-year pro-
gression-free survival: 44%),34 or even myeloablative condi-
tioning regimens (progression-free survival between 31%
and 54%),9-11 in patients with conditions rather similar to
those in our study. Our results are also noteworthy if com-
pared with those of studies based on non-myeloablative
conditioning (progression-free survival ranging from 32% to
44% in two large recent studies).6,18 In brief, our conditioning
platform allows for substantial disease control, as compared
with that achieved in previous studies.
Despite the patients’ older ages and high rate of comor-
bidities, non-relapse mortality in this cohort was low: 2.4%
at day 100 and 14% at 2 years, likely due to a low incidence
of severe acute and chronic GVHD. These results are similar
to the non-relapse mortality reported in patients undergoing
true non-myeloablative conditioning regimens (1-year non-
relapse mortality under 16%),16,18,35 which are known to be
associated with lower non-relapse mortality than that in
myeloablative conditioning regimens. If compared with
studies based on reduced-toxicity conditioning, our results
were even more satisfactory (1-year non-relapse mortality:
19% in a recent study by Alatrash et al.).34
Taken together, the relatively low non-relapse mortality
and relapse incidence led to a 61.8% overall survival at 2
years, which compares favorably with results from the
above-cited studies including reduced-intensity conditioning
(overall survival between 26% and 60%)5,10,12,15,36-40 and mye-
loablative conditioning (overall survival between 35% and
56%).11,34,41
Our patients received either reduced-intensity condition-
ing or reduced-toxicity conditioning. A comparison between
the two groups did not reveal significant differences regard-
ing disease type, disease status, donor type, or stem cell
source although there was a difference in age at transplanta-
tion (Table 1). Surprisingly, we found a lower non-relapse
mortality in the reduced-toxicity conditioning group (busul-
fan dose: 390 mg/m2 or 520 mg/m2). However, due to the
retrospective nature of this study, it cannot be concluded
that more intensive conditioning leads to lower non-relapse
mortality rates. The choice of the busulfan dose was, in fact,
based on physicians’ assessment, and many patients were
included in trials at the time in which physicians were
advised to reserve higher doses of busulfan for patients
under 55 years of age or who had no comorbidities. The
indications for more intensive conditioning were extended
to older patients and those with comorbidities when it
became evident that the regimens were well tolerated. The
difference in age at transplantation between the two groups
could also explain the difference in non-relapse mortality
rates: patients who received a lower busulfan dose were
older (median age 60.4 years) than those who received more
intensive conditioning (median age 47.6 years; P<0.001).
Only a prospective, randomized study would be able to
show whether or not more intensive conditioning is associ-
ated with a higher non-relapse mortality. We can, however,
conclude that higher doses of busulfan were not associated
with greater toxicity in selected patients.
We did not detect any significant differences in disease
control between patients given reduced-intensity or
reduced-toxicity conditioning. This could be explained by
the retrospective nature of our study and by the fact that
reduced-toxicity conditioning was often chosen by clinicians
in cases of diseases with higher risk of relapse, based on pre-
vious studies showing a higher relapse rate when using non-
myeloablative conditioning regimens.4,11,12 However, the
impact of greater myeloablation on relapse rates deserves
further prospective evaluation.
Patients received an intermediate dose of rabbit anti-thy-
moglobulin (5 mg/kg). This in vivo T-cell depletion has been
controversial. Its use has been shown to decrease GVHD
incidence in several studies23,37,42-44 without increasing overall
survival or progression-free survival, perhaps because of an
impaired graft-versus-leukemia effect. Given that our
patients were at high risk of GVHD and non-relapse mortal-
ity because of their ages and comorbidities, the use of rabbit
anti-thymoglobulin was of particular interest. Our results
support previous data suggesting that a dose of 5 mg/kg
does not dramatically increase relapse rates. Moreover, we
determined that most patients (54%) who suffered from
chronic GVHD and who were alive more than 1 year after
transplantation were able to discontinue steroid therapy
within 1 year, which reflects the favorable outcome of their
chronic GVHD. Contrary to previously published observa-
tions, we did not see a high proportion of severe, fatal infec-
tions;45 only four patients died from infection without
GVHD. A dose of 5 mg/kg of rabbit anti-thymoglobulin
may, therefore, be considered to be in an optimal dose win-
dow, allowing for efficient GVHD prevention and a low
number of related infections and relapses, as previously
reported.20
Our study does have several obvious biases: it was a ret-
rospective, non-randomized study, and molecular markers
such as NPM1 and FLT3-ITD were not available for all
patients, which made it difficult to analyze the prognosis
impact of those markers in our cohort. As it was not a
prospective, randomized study, the choice of the condition-
Table 3. Multivariate analysis for progression-free survival.
Progression-free survival
HR 95% CI P value
Disease status
Non CR1 (n=72) (vs. CR1) 2.03 1.13-3.65 0.017
Karyotype
Favorable (11) (vs. intermediate karyotype) 0.45 0.13-1.49
Unfavorable (46) (vs. intermediate karyotype) 2 1.23-3.25 0.005
Age
> 55 years (n=89) (vs.≤55 years) 0.96 0.55-1.68 0.89
Total dose of busulfan
390 or 520 mg/m2 (n=59) (vs. 260 mg/m2) 0.61 0.34-1.09 0.09
Disease type
MDS (n=41) (vs. AML) 1.02 0.55-1.9 0.95
P value <0.05 were considered statistically significant and are shown in bold. CR1: first complete
remission. AML:  acute myeloid leukemia, MDS: myelodysplastic syndrome. 
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ing regimen was based on physicians’ appraisal, which lim-
its the assessment of the impact of different individual con-
ditioning regimens. In addition, a busulfan pharmacokinetics
analysis would be of great interest and could help to deter-
mine the effect of busulfan dose in terms of both disease
control and transplant-related morbidity and mortality.
However, the strength of our results lies in the homogeneity
of the cohort, with regards to disease type and transplant
characteristics, which makes our conclusions more robust.
Only two transplantation centers were included in the study,
which led to homogeneous supportive care and evaluation
of the patients.
We conclude that a conditioning regimen including flu-
darabine, busulfan, and rabbit anti-thymoglobulin (5 mg/kg)
is well tolerated and can lead to long-term disease control.
Higher busulfan doses were not associated with greater tox-
icity. Such a regimen may be effective for tuning the dose
intensity by modulating the busulfan dose according to dis-
ease and toxicity risks. The impact of dose-intensity on post-
transplant outcome remains a central issue and only a ran-
domized, prospective study would be able to provide a final
answer to this important question. A randomized multicen-
ter study of this nature is now underway in France (Study
AAA-IPC 2°11-003, EUDRACT number: 2013-001935-36)
and aims to compare different doses of busulfan in a com-
mon conditioning platform based on fludarabine, three dif-
ferent doses of busulfan (260 mg/m2, 390 mg/m2, and 520
mg/m2), and rabbit anti-thymoglobulin (5 mg/kg). To date, a
few patients have been randomized into this large, prospec-
tive study, which will help to determine whether higher
doses of busulfan could lower relapse risk without increas-
ing transplant-related toxicity.
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